PMID- 18004136
OWN - NLM
STAT- MEDLINE
DCOM- 20080226
LR  - 20181201
IS  - 0271-0749 (Print)
IS  - 0271-0749 (Linking)
VI  - 27
IP  - 6
DP  - 2007 Dec
TI  - A randomized, double-blind, placebo-controlled trial of augmentation topiramate 
      for chronic combat-related posttraumatic stress disorder.
PG  - 677-81
AB  - BACKGROUND: Topiramate, a novel anticonvulsant, has been reported to rapidly 
      reduce symptoms of posttraumatic stress disorder (PTSD) in an open-label trial. 
      The present study was designed as a test of topiramate's efficacy as adjunctive 
      therapy in a 7-week, randomized, double-blind, placebo-controlled trial. METHODS: 
      Forty male veterans with PTSD in a residential treatment program were randomized 
      to flexible-dose topiramate or placebo augmentation. The primary outcome measures 
      were PTSD symptom severity and global symptom improvement. RESULTS: Baseline 
      Clinician-Administered PTSD Scale scores were 62.1 +/- 13.9 for placebo and 61.0 
      +/- 22.2 for topiramate. There was a high dropout rate from the study (55% 
      topiramate; 25% placebo), with 40% of topiramate and 10% of placebo dropping 
      because of adverse events (AEs). No significant treatment effects of topiramate 
      versus placebo were observed for the primary treatment outcomes. Subjects 
      reporting central nervous system-related AEs and with higher baseline severity of 
      depression were more likely to discontinue because of AEs. CONCLUSIONS: Primary 
      outcome measures failed to demonstrate a significant effect for topiramate over 
      placebo; however, high dropout rate in the treatment group prohibits definitive 
      conclusions about the efficacy of topiramate in this population.
FAU - Lindley, Steven E
AU  - Lindley SE
AD  - Department of Psychiatry, Stanford University School of Medicine, Stanford, CA, 
      USA. lindleys@stanford.edu
FAU - Carlson, Eve B
AU  - Carlson EB
FAU - Hill, Kimberly
AU  - Hill K
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Psychopharmacol
JT  - Journal of clinical psychopharmacology
JID - 8109496
RN  - 0 (Anticonvulsants)
RN  - 0H73WJJ391 (Topiramate)
RN  - 30237-26-4 (Fructose)
SB  - IM
MH  - Age Factors
MH  - Anticonvulsants/adverse effects/therapeutic use
MH  - Chronic Disease
MH  - Combat Disorders/*complications/psychology
MH  - Double-Blind Method
MH  - Drug Administration Schedule
MH  - Exanthema/chemically induced
MH  - Fructose/adverse effects/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Patient Dropouts/statistics & numerical data
MH  - Psychiatric Status Rating Scales
MH  - Severity of Illness Index
MH  - Stress Disorders, Post-Traumatic/*drug therapy/etiology/psychology
MH  - Time Factors
MH  - Topiramate
MH  - Treatment Outcome
MH  - Urinary Tract Infections/chemically induced
MH  - *Veterans
EDAT- 2007/11/16 09:00
MHDA- 2008/02/27 09:00
CRDT- 2007/11/16 09:00
PHST- 2007/11/16 09:00 [pubmed]
PHST- 2008/02/27 09:00 [medline]
PHST- 2007/11/16 09:00 [entrez]
AID - 00004714-200712000-00017 [pii]
AID - 10.1097/jcp.0b013e31815a43ee [doi]
PST - ppublish
SO  - J Clin Psychopharmacol. 2007 Dec;27(6):677-81. doi: 10.1097/jcp.0b013e31815a43ee.